The DOI matches its Crossref record; 39 of the 40 references it cites were found in a registry or an index.
Galantamine-loaded solid–lipid nanoparticles for enhanced brain delivery: preparation, characterization, in vitro and in vivo evaluations
Open accessAbstract
Galantamine hydrobromide, a promising acetylcholinesterase inhibitor is reported to be associated with cholinergic side effects. Its poor brain penetration results in lower bioavailability to the target site. With an aim to overcome these limitations, solid-lipid nanoparticulate formulation of galantamine hydrobromide was developed employing biodegradable and biocompatible components. The selected galantamine hydrobromide-loaded solid-lipid nanoparticles offered nanocolloidal with size lower than 100 nm and maximum drug entrapment 83.42 ± 0.63%. In vitro drug release from these spherical drug-loaded nanoparticles was observed to be greater than 90% for a period of 24 h in controlled manner. In vivo evaluations demonstrated significant memory restoration capability in cognitive deficit rats in comparison with naive drug. The developed carriers offered approximately twice bioavailability to that of plain drug. Hence, the galantamine hydrobromide-loaded solid-lipid nanoparticles can be a promising vehicle for safe and effective delivery especially in disease like Alzheimer's.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The maximum drug entrapment of these SLNs was ~83 %, with greater than 90% drug release in 24 h.”
From Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles (2019) · cites this paper as [104]
In the citing paper
“Interestingly, SLNs loaded with galantamine hydrobromide demonstrated enhanced bioavailability (two times higher than that of the pure drug) and improved memory and cognition in animals.104”
From Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles (2019) · cites this paper as [104]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Place navigation impaired in rats with hippocampal lesions
Morris, R. G. M., Garrud, P., Rawlins, J. N. P., & O'Keefe, J. (1982) · Nature · doi:10.1038/297681a0 · Cited by 6,340
Raskind (2000) · doi:10.1212/wnl.54.12.2261 · Cited by 870
The Relationships Between Age, Sex, and the Incidence of Dementia and Alzheimer Disease
Gao, S., Hendrie, H. C., Hall, K. S., & Hui, S. L. (1998) · Archives of General Psychiatry · doi:10.1001/archpsyc.55.9.809 · Cited by 782
Nanoparticle Surface Charges Alter Blood–Brain Barrier Integrity and Permeability
Lockman, P. R., Koziara, J. M., Mumper, R. J., & Allen, D. D. (2004) · Journal of drug targeting · doi:10.1080/10611860400015936 · Cited by 742
Wilcock, G. K., Lilienfeld, S., & Gaens, E. (2000) · BMJ · doi:10.1136/bmj.321.7274.1445 · Cited by 623
Potential of solid lipid nanoparticles in brain targeting.
Kaur, I. P., Bhandari, R., Bhandari, S., & Kakkar, V. (2008) · Journal of Controlled Release · doi:10.1016/j.jconrel.2007.12.018 · Cited by 615
Manufactured nanoparticles: their uptake and effects on fish—a mechanistic analysis
Handy, R. D., Henry, T. B., Scown, T. M., Johnston, B. D., & Tyler, C. R. (2008) · Ecotoxicology · doi:10.1007/s10646-008-0205-1 · Cited by 447
Feng, S., & Huang, G. (2001) · Journal of Controlled Release · doi:10.1016/s0168-3659(00)00364-3 · Cited by 400
Wilson, B., Samanta, M. K., Santhi, K., Kumar, K. P. S., Paramakrishnan, N., & Suresh, B. (2008) · Brain Research · doi:10.1016/j.brainres.2008.01.039 · Cited by 363
Maelicke, A., Samochocki, M., Jostock, R., Fehrenbacher, A., Ludwig, J., Albuquerque, E. X., & Zerlin, M. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01109-4 · Cited by 303
Research works printed but not linked: 4
- Muller RH, 1993, Proc Int Symp Control Rel Bioact Mater, 20, 480
- Patel KB, 2010, J Chem Pharm Res, 2, 36
- Shi F, 2012, Int J Nanomedicine, 7, 2033
- Sruthi N, 2015, IJPCBS, 5, 63
Cited by
Sorted by citations
Items 101–139 of 139
Solid Lipid Nanoparticles: A Modern Approach for the Treatment of Neurodegenerative Diseases
D’souza, A. A. (2018) · Springer eBooks · doi:10.1007/978-3-319-99602-8_9 · Cited by 6
Emerging nano-derived therapy for the treatment of dementia: a comprehensive review
Ahmad, S., Ahmad, L., Adil, M., Sharma, R., khan, S., Hasan, N., & Aqil, M. (2025) · Drug Delivery and Translational Research · doi:10.1007/s13346-025-01863-3 · Cited by 4
Nanomedicine for Treating Major Brain Diseases: Advances and Future Directions
Sagar, G., Wilson, B., Mukundan, G. K., Divekar, K., & Jenita⃰, J. J. L. (2025) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5c00277 · Cited by 4
Bag, J., Mukhopadhyay, S., Nandi, G., & Tun, H. M. (2026) · Drug Delivery · doi:10.1080/10717544.2026.2614585 · Cited by 4
Alzheimer’s Disease: Evolving Therapeutics, Scientific Progress, and Key Challenges
Sai Yasasvi, K., Goswami, A. K., Prasad, M. R., Chauhan, V. S., & Yadav, N. (2026) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c02468 · Cited by 4
Nanotechnology Based Approaches for Neurodegenerative Disorders: Diagnosis and Treatment
Hernando, S., Herrán, E., Pedraz, J. L., Igartúa, M., & Hernández, R. M. (2017) · Springer eBooks · doi:10.1007/978-3-319-57696-1_3 · Cited by 4
Solid Lipid Nanoparticles: A Nano Drug Carrying System in Treatment of Nervous Diseases
Yin, Y., Zhang, J., & Zhou, X. (2022) · Highlights in Science Engineering and Technology · doi:10.54097/hset.v11i.1266 · Cited by 3
Nano chitosan anchored copper-ferrite: a smart magnetic nanocomposite agent for drug delivery
Adebayo, A. O., Alli, Y. A., Bamisaye, A., & Adewuyi, S. (2023) · Emergent Materials · doi:10.1007/s42247-023-00584-y · Cited by 3
Pharmacokinetics and pharmacodynamics of various novel formulations targeting Alzheimer's disease
Gawade, A. R., Polshettiwar, S. A., Hingalajia, H., Prajapati, B. G., & Singh, A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13205-6.00027-3 · Cited by 3
Current treads of targeted nanoparticulate carriers for the treatment of Alzheimer’s disease
Gheidari, D., & Bayat, M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85544-0.00005-8 · Cited by 3
Kıymacı, M. E., Topal, G. R., Eşi̇m, Ö., Bacanli, M. G., Özkan, C. K., Erdem, O., Savaşer, A., & Özkan, Y. (2022) · Archives of Industrial Hygiene and Toxicology · doi:10.2478/aiht-2022-73-3667 · Cited by 3
Nanomedical drug delivery for neurodegenerative disease
Kaur, N., Kumar, V., Mahender, T., Maji, I., Mahajan, S., Aalhate, M., Singh, P. K., & Sahu, S. K. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-85544-0.00016-2 · Cited by 2
Solid lipid nanoparticles-based drug delivery for dementia
Yüksel, N., Bayındır, Z. S., & Amasya, G. (2022) · Elsevier eBooks · doi:10.1016/b978-0-12-824331-2.00008-x · Cited by 2
Cortinhas, J., Pêgo, A. P., & Moreno, P. M. D. (2020) · Elsevier eBooks · doi:10.1016/b978-0-12-818084-6.00009-x · Cited by 2
Tyagi, S., Kumar, J., & Kumar, S. (2025) · Journal of Dispersion Science and Technology · doi:10.1080/01932691.2025.2580488 · Cited by 1
Al‐allaq, A. A., Hassan, H. A., Hidayet, H. M., Abdulhakeem, A. A., & Ahmad, Z. A.-A. Q. (2026) · Micro · doi:10.3390/micro6030065 · Cited by 1
Afnan, U., Khan, M. S., Swaliha, C. A., Manzoor, U., Mumtaz, I., Dar, M. J., & Maqbool, T. (2023) · Elsevier eBooks · doi:10.1016/b978-0-443-15177-4.00002-9 · Cited by 1
Baher, N. K., Heikal, L., El-Salamouni, N. S., Gaafar, P. M. E., Bakr, B. A., Badae, N. M., & ElGamal, S. S. (2025) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2025.107925 · Cited by 1
Phullay, P., Panwar, R., Bajwa, S., Wadhwa, K., Chauhan, P., Pahwa, R., Kriplani, P., Rajak, H., Awasthi, R., & Dureja, H. (2026) · Regenerative Engineering and Translational Medicine · doi:10.1007/s40883-026-00616-z · Cited by 1
Lipid nanocarriers for the delivery of drugs to the nervous system
Basha, M., AbouSamra, M. M., & Kamel, R. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-95171-5.00005-4 · Cited by 1
Nakhate, K. T., Mangrulkar, S. V., Badwaik, H. R., Choudhary, R., Baghel, M., Goyal, S. N., & Ajazuddin, M. (2023) · Elsevier eBooks · doi:10.1016/b978-0-323-99125-4.00011-1 · Cited by 1
Current Perspectives of Nanotherapeutics for the Treatment of Alzheimer’s Disease
Mishra, S., Senthilkumar, D., & Yadav, V. K. (2024) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815256505124010010 · Cited by 1
Nanolipidic Carriers as Potential Drug Delivery Vehicles in Alzheimer’s Disease
Talegaonkar, S., Gautam, N., Varshney, V., Sharma, S., & Bhattacharyya, A. (2019) · Springer eBooks · doi:10.1007/978-3-030-30930-5_13
Nanomedicines encountering HIV dementia: A guiding star for neurotherapeutics
Jadhav, S. S., Yenorkar, N. Y., Bondre, R. M., Karemore, M. N., & Bali, N. R. (2022) · Journal of Drug Delivery Science and Technology · doi:10.1016/j.jddst.2022.103315
Role of novel drug delivery systems in managing Alzheimer's disease
Chahat, Shome, A., & Chawla, P. A. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13474-6.00031-7
Applications of Nanotechnology in Degenerative Disorders of the Brain
Lopes, D. H. J., Sisi, F. Y., Mehrabian, A., Davoudkhani, M., Noroozıan, M., Khawaja, A. M., & Heiss, J. D. (2024) · Springer eBooks · doi:10.1007/978-3-030-80662-0_30
Singh, S., Sharma, N., Singh, V. P., & Sharma, A. (2025) · Current Nanomedicine · doi:10.2174/0124681873330947241230054603
REVOLUTIONIZING ALZHEIMER’S THERAPEUTICS: FROM MICROTECHNOLOGIES TO AI-DRIVEN INNOVATIONS
Lahiri, A., Balamuralidhara, V., Manohar, S. K., & R., A. A. (2025) · International Journal of Applied Pharmaceutics · doi:10.22159/ijap.2025v17i3.53726
Tripathi, A., & Sahu, O. (2025) · AIP conference proceedings · doi:10.1063/5.0272798
Shalaby, K. (2021) · Open Research Knowledge Graph (ORKG) · doi:10.48366/r148381
Study of The Application of Microplasma for Intranasal Drug Delivery to The Brain
Sadiq, A. H. (2025) · Institutional Repositories DataBase (IRDB) · doi:10.14945/0002001782
Nanocarriers mediated DNA repair mechanism against neurological disorders
Bora, S., Jadav, M., Kulhari, H., & Pooja, D. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-33623-2.00009-x
Targeting Autophagy in Alzheimer's Disease: Role of the AMPK/mTOR Pathway and Drug Repurposing
Dubey, A., Chaurasia, A., Ansari, Z. A., Kushwaha, S. K., Saraf, I., Kashaw, S. K., Swami, R., & Kushwah, V. (2026) · Drug Development Research · doi:10.1002/ddr.70344
Machado, M. J., Alves, A., Amaral, M. H., Saraiva, N. M., & Costa, P. C. (2026) · Future Pharmacology · doi:10.3390/futurepharmacol6030037
Reshaping the immune landscape: next-generation microglia-targeted therapies for Alzheimer’s disease
Wu, J., Zhao, J. J., Chen, S. Y., & Xu, F. (2026) · Biological Research · doi:10.1186/s40659-026-00716-8
Ahmed, H., & Alexander, A. (2026) · Journal of Dispersion Science and Technology · doi:10.1080/01932691.2026.2736298
Ebrahimi, M., Javan, M., & Alijanianzadeh, M. (2026) · Journal of Toxicology · doi:10.1155/jt/3248563
Ahmad, S., Ahmad, L., Shahrukh, M., Hasan, N., & Aqil, M. (2026) · RSC Pharmaceutics · doi:10.1039/d6pm00385k
Developing precision nanoparticle-based drug delivery systems for Alzheimer's disease therapy
Shan, Q., Zheng, W., Yao, W., Bai, Y., Ding, W., Wang, J., & Bai, F. (2026) · Materials Today Bio · doi:10.1016/j.mtbio.2026.103789
Metadata
- Authors
- Misra, S., Chopra, K., Sinha, V. R., & Medhi, B.
- Affiliations
- Post Graduate Institute of Medical Education and Research (IN)
- Panjab University (IN)
- Corresponding author
- Medhi, Bikash
- Venue
- Drug Delivery
- Publisher
- Informa UK Limited
- Published
- 2015-09-25
- Volume
- 23
- Issue
- 4
- Pages
- 1434-1443
- ISSN
- 1071-7544 (ISSN-L)
- 1521-0464
- OpenAlex
- W1867774233
- Cited by
- 136
- References
- 40
- Citations by year
- 2026: 12 · 2025: 14 · 2024: 11 · 2023: 19 · 2022: 29 · 2021: 10 · 2020: 16 · 2019: 9 · 2018: 7 · 2017: 6 · 2016: 3
- FWCI
- 2.96
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Drug Delivery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Sun Pharma
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advancements in Transdermal Drug Delivery
- Keywords
- galantamine hydrobromide, solid lipid nanoparticles, brain drug delivery, acetylcholinesterase inhibitors, Alzheimer's disease, encapsulation efficiency, controlled drug release, cognitive impairment, bioavailability enhancement, nanocarriers
- MeSH terms
- Animals, Brain, Cholinesterase Inhibitors, Drug Carriers, Galantamine, Lipids, Drug Delivery Systems, Rats, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
